Company / EPS (Diluted)
Sunshine Biopharma Inc. EPS (Diluted) History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$351.36
FY2024
5-year range
-$351.36 / -$1.76
FY2022-FY2024
Trend
-19863.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) changed -19864% YoY in FY2024, a notable deviation from the 2-year average annual change of -9900%.
Based on SEC 10-K filings.
-351.36 in FY2024.
Declined from $-4.76 to $-351.36 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, eps (diluted) decreased 19863.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$351.36 | -19863.6% |
| FY2023 | -$1.76 | +63.0% |
| FY2022 | -$4.76 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026